{"name":"Keros Therapeutics, Inc.","slug":"keros-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Dose A KER-012","genericName":"Dose A KER-012","slug":"dose-a-ker-012","indication":"Other","status":"phase_2"},{"name":"Dose B KER-012","genericName":"Dose B KER-012","slug":"dose-b-ker-012","indication":"Treatment of hypoparathyroidism","status":"phase_2"},{"name":"Dose C KER-012","genericName":"Dose C KER-012","slug":"dose-c-ker-012","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Dose A KER-012","genericName":"Dose A KER-012","slug":"dose-a-ker-012","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Dose B KER-012","genericName":"Dose B KER-012","slug":"dose-b-ker-012","phase":"phase_2","mechanism":"Dose B KER-012 is a bone morphogenetic protein (BMP) agonist.","indications":["Treatment of hypoparathyroidism"],"catalyst":""},{"name":"Dose C KER-012","genericName":"Dose C KER-012","slug":"dose-c-ker-012","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOVExJQ0tfMFJObmFMTkhzZ1FvYlFwN2VsVFN6bUQ5b3ZzOHBtd3VuUjE0Rjltc2M0emFHVG92TmRYUE1ZVmVqYW04ZVhuR1IyWHhSdXBKUGlnRnJldUdCbXUzYURucWRnbFR4SDZaajFmYXlyMUIxdmVieWRKdUtmM3RxOS1IMTgyb0V4bWt3Q1hNOXBpVmpudg?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Myelofibrosis Pipeline 2026: Therapies Under Investigation, - openPR.com","headline":"Myelofibrosis Pipeline 2026: Therapies Under Investigation,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNSE9UdnBCS1FpdG81QVVPeGNGM3lEZmFWeXlrMXltb0ZOa2lUZlg0OFdPdHVKQVdBR3BtbUsxNmFwbU5qS3ZMSUZTMXdDb25uYVRiX01iZkE4a1NkTG1VY1l2eHJmUy1sSnZickpqYm5oaWNlYXdCckJvMF9NYTItSjNTa1Y5Vng4MmFuWGRILWgwTGgxa0UzUWI5STR5bmgzREp3U2lnMy1BX3ZwY2FwWG0xU3hQT2pGSGRmWlVn?oc=5","date":"2026-02-18","type":"earnings","source":"TradingView","summary":"Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - TradingView","headline":"Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPSTN6VC1YLWpMbTNRbHVVNVhra3hRY3A5Ukx3ejNtTm5ZOWhFSC1kOGhxMUEyN1FucTFJRGJaczc4QlBiVmVsSWJUYXVYMkpHWHYyeHlTdHl1ZjVlamJyb3oxWl9mcmNvbVB6RThwTkQxX1JVbTZhQURiSFVJcFB1NjR3T0llSVRqdy1yRXYzMWFWWTRtUFE4?oc=5","date":"2026-01-15","type":"pipeline","source":"Finviz","summary":"KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Finviz","headline":"KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-18","type":"pipeline","source":"simplywall.st","summary":"Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st","headline":"Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOb2M3OC1vckQ2dzV0a19Ha1ZfalAtUmlKLWQ0R2tMMFVXMWM1cjZuVld2djJvNHp1YW1teUZQZUZHRHZ4VGQtbnByeGF1aWxZU3JxTW0waG9CNURnbDNwdkZzVTN4YXJFTUg0TU9QMUlrazVkeVU3c1BWSWRTMWN2eGVzUDVGWDlibjd4VFBvTEpRZE1CQ1pXa3dMM09GcnAwa0prRWZlY1g3OFh4d1k2MVdsbnl4Y1prTTFQMHZQUmxpRGhYUkxRMFZXTS0wZldPTzBLLTJuLVJDTEotMHBVY3BiNA?oc=5","date":"2025-10-15","type":"pipeline","source":"GlobeNewswire","summary":"Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital - GlobeNewswire","headline":"Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPQjJ2VUhMM1Q5LUpUZWtQbERDaUNmenM4b3htblk1Slk2eHdpRjVoNk5iWHZzZ2NBWkNlUi1SUFZacERUaHBRemU5cFdGSUk5b3JaeTFsYnM4VUxrd0ZoVFRpUEw1bE5VcjU5ZG9FUjc3dkNSZHNxTzNFR2VSR0xfQmNsbw?oc=5","date":"2025-10-07","type":"pipeline","source":"BioWorld News","summary":"Takeda ditches cell therapy business - BioWorld News","headline":"Takeda ditches cell therapy business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPUnlJQUlKRGFvOFk2Y0hCbkxIcVpFVTRYay1SSkNHZmw1RzZjUlQ5d2U5SURLaDhnd1pTNWFkOGlKTkdsaHlDMDFMVGNEUmJydUotQmRyck8xTVNhOHY4V0w3WGZhcFVnZEFBYnU3RlBjTVppa0d4Um1FbTEyLVpmeEdfdlptSjFUZHc?oc=5","date":"2025-09-25","type":"pipeline","source":"seekingalpha.com","summary":"Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) - seekingalpha.com","headline":"Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQQ0J4WnNadVpfazgxTEtkQWpjRFdqaFM1bG01QThham9NelZiRERTVzEzYjkxR0UwcEN1NkduLWJKNmRRazRvRDV4YTA1SXhqNkp6MHdyOWRQdUFaelBwNDI1Wm84NldHT3lDUUpBSjR0TmpvZTM5WFVtSjl4MWpWOWx4dG4wNnd2STI0UlVwUWhwVUhral9JaUVJLWNSSzNVSDBxRGNDWQ?oc=5","date":"2025-04-10","type":"pipeline","source":"Pharmaceutical Technology","summary":"Keros Therapeutics considers sale amid investor pressure - Pharmaceutical Technology","headline":"Keros Therapeutics considers sale amid investor pressure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNTnVhQ05rZlhGdXNnUzlwTFpkX094c1FaWWlQazhNRmdwZ0dEZGd2b0xXZkZKWXZLTG9XZEdkbFVmVFdTSTE3U3dHblBHdHVBaGhyOUNpWkFuSU9BOWNJQ0VkOUN3NVVhLTFCd1FJMzBBcHpxYnZ3dHJVcEV4NmRTRjVwd2hGdXc1V1dKT09QajdoNUc0NjZDNUhIZFprdEoxRmJUZUdyU2lOR1NrS1JCclkwbw?oc=5","date":"2024-12-12","type":"pipeline","source":"BioPharma Dive","summary":"Keros shares collapse on ‘unanticipated’ setback for lung disease drug - BioPharma Dive","headline":"Keros shares collapse on ‘unanticipated’ setback for lung disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQUC01Y3RQRU1iWXFWa283dzNUdE0yOU1hR0hPbnFHMjZDWXJQZ1NxNlJLS2hENEpwNFF4TVRLMThxYzRCX2lfbzRLYTRPUnJEb19oVzQ0end4VDhKYXFENUlWODFwU2NwcW03UUNMa0xoVkd6eGo3NFkydnp1RFJpemhEenBpOFQtWkNsaUVWVk9TR0pLVzhyd2RWY2s0OTdYY2lNem9GeXVyU0VGcGMzeWRCN0JDaHlnUDc4TVhqOURiV2xBMXlaRGZWcVF0SGhxX0d3ZkthdUJ5SW81MWxHc0FR?oc=5","date":"2024-12-12","type":"trial","source":"Reuters","summary":"Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial - Reuters","headline":"Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOdGtCbF9PZFN4STNienExUWxLSThDOGNlMVJjOFJqdy1YS181a0dEYVFhOGFOOXczZEtvcmIwMnF6YnV4ZUNGRGRweDhvemM2eUplWGlGTW8zeWR3UHBzSGRRQTNDTG1CcUdSTGRGMDNuRWlhUHdaMHgyRmJXQ0s3UGJMcFBpOU9aN01heUtYU0tMR1hPdUlDM1o3Tk8?oc=5","date":"2024-12-04","type":"pipeline","source":"Contract Pharma","summary":"Takeda, Keros Enter Exclusive Elritercept Agreement - Contract Pharma","headline":"Takeda, Keros Enter Exclusive Elritercept Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNSUVBU0N2WklPZ3RxOW03ZUl2ZU5JckNhQnBEUlJ6bmZObEdjWTdSdnoxVW4xU0Z5UGpUUXlJOHUtV3NuZ2VxYTl5TXNISUZCOWNabkc3SmNZMjJxYjVDMElIRzhldWJ5ckVmaElRMlhLbDhydG5wb0xIc0VMaEFvWWhRMzRRRGRkRkI3c2ZVS2xCTkRqaFNFQVhuS2RjV2MxN0ZBLUU1NjdRUlZoQ2pfZDVKV2x5Zw?oc=5","date":"2024-12-03","type":"pipeline","source":"MedCity News","summary":"Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond - MedCity News","headline":"Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}